We have planned for a three-stage approach to a liquidity event, depending on the success of our ICO raise:

Stage 1
The minimum planned amount to close the ICO is US$4.35 M. This will be sufficient to complete GMP manufacture, IND-enabling experiments and IND submission:
Stage 2
The funds needed to run a Phase 1 trial is US$3.8M and will allow for proof of safety of our drug:
Stage 3
the funds needed to run a Phase 2 trial (clinical proof of concept) is US$24.1: